3 results
Primary:Cohort 1: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days isadministered to patients with ED-SCLC that haveplatinum-sensitive disease* Cohort 2: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days…
Main objective:To assess the long-term safety and tolerability of AAV5-hRKp.RPGR in individuals with RPGR-XLRPTo assess the long-term efficacy of treatment with AAV5-hRKp.RPGR in individuals with RPGR-XLRP based on assessments of functional vision…
Primary:To assess the effect of bilateral treatment with AAV5-hRKp.RPGR on functional vision as measured by vision-guided mobility assessment.Secondary:To assess changes after treatment administration in retinal function, functional vision, visual…